| 发明名称 |
Compounds for the treatment of conditions associated with DGAT1 activity |
| 摘要 |
The present invention relates to novel crystalline forms of salts of 2-((1R,4R)-4-(4-(5-(benzo[d]oxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl)acetic acid and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans. |
| 申请公布号 |
US8987459(B2) |
申请公布日期 |
2015.03.24 |
| 申请号 |
US201414152282 |
申请日期 |
2014.01.10 |
| 申请人 |
Novartis AG |
发明人 |
Capacci-Daniel Christina;DeLaCruz Marilyn;Gong Baoqing;Jain Akash;Lu Yansong;Zhang Lijun |
| 分类号 |
C07D413/00;C07D413/12;A61K31/4439;A61K45/06 |
主分类号 |
C07D413/00 |
| 代理机构 |
|
代理人 |
Roth Joshua |
| 主权项 |
1. A maglumine salt of 2-((1R,4R)-4-(4-(4-(5-(benzo[d]oxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl)acetic acid represented by formula (Ia): |
| 地址 |
Basel CH |
